The exploration of nanotechnology-based therapies has unveiled potential solutions to overcome the drawbacks of conventional anti-obesity medications, including their nonspecific actions and the temporary impact on weight reduction
Studies suggest that various molecular pathways are involved in IC/BPS, including the JUN N-terminal kinase (JNK) pathway, transient receptor potential (TRP) channels, activated mast cells, mucosal signalling, circadian rhythm regulation, inflammation and neural dysregulation
To place these changes in a functional context, we again generated a custom list of pathways by combining publicly available gene lists related to brain function and performed GSEA analysis ( Figure 3C
DeVito, Linda S
Having characterised the phenotype driven by the Ubx/U1-70K genetic interaction, we assessed the ability of Ubx transgenes to rescue the muscle alteration (Figure 1D-G)
Store reconstituted solutions below 4C (39F) Do not freeze-thaw the peptide repeatedly (temperature fluctuations may affect peptide integrity) Note: Under appropriate laboratory conditions, reconstituted Glow 70 Peptide solutions may remain suitable for use for up to 30 days
